The adoption of sacubitril/valsartan for heart failure management has been slow, potentially due to its high cost.
Adoption of sacubitril/valsartan after Food and Drug Administration approval has been slow and may be associated with the high cost.
Sangaralingham et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: